The angiotensin-converting enzyme (ACE) inhibitor and angiotensin II (Ang II) type I receptor (AT1R) blocker are part of therapeutics for combating CKD progression, as circulating Ang II is reported to promote EC dysfunction and hypertension as well as extracellular matrix (ECM) dysregulation [3]. Here, ACE is linked to hypertensive disorder.